#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials
Breakpoints
00:00
E-Petroboryl, A&2 Therapeutics
E-petroboryl, A&2 Therapeutics is a bioformaceutical company that actually uses a boron chemistry platform. This compound has a novel mechanism of action where an enzyme involved in protein synthesis called lucil tRNA synthetase is actually locked together to the terminal adenosine ribose of tRNA. In terms of in vitro activity, it has MICs demonstrated between 0.25 and 8. It has also excitingly demonstrated activity against chlorothermysin and ama casein resistant isolates.
Transcript
Play full episode
